Rapport Therapeutics director acquires 20,400 RAPP shares at ~$24.48

Rhea-AI Filing Summary

Rapport Therapeutics director Reid M. Huber purchased 20,400 shares of RAPP common stock on 09/12/2025 at a weighted-average price of $24.4791 per share, with transaction prices ranging from $24.23 to $24.50. After the purchase Huber beneficially owns 20,400 shares directly. No derivative securities were reported. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person on 09/15/2025. The filer notes the reported price is a weighted average and offers to provide a breakdown of the individual trade prices on request.

Positive

• Director purchase disclosed: 20,400 shares acquired, signaling insider buying activity
• Transparent pricing: Weighted-average price $24.4791 with range $24.23–$24.50 disclosed
• Complete Form 4 details: Transaction date, resulting ownership, and signature by attorney-in-fact provided

Negative

• None.

Insights

Financial Analyst

TL;DR: A routine insider purchase of 20,400 RAPP shares at about $24.48; informative but not clearly material without context.

This Form 4 documents a straightforward open-market acquisition by a company director. The weighted-average price and disclosed range provide transparency on execution. Without information on the director's prior holdings, the size of the purchase relative to outstanding shares, or firm valuation metrics, it is difficult to assess material market impact. For investors, this is a signal of insider participation but not definitive evidence of a change in fundamentals.

Corporate Governance Expert

TL;DR: Properly filed disclosure of director purchase; procedural compliance and transparency are evident.

The Form 4 appears complete for the reported transaction: it lists the reporting person, issuer and ticker, transaction date, amount acquired, weighted-average price range, and resulting beneficial ownership. The signature by an attorney-in-fact is noted. There are no derivative transactions or indications of stock-based compensation exercises. From a governance perspective, the filing meets disclosure obligations and enhances market transparency.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Huber Reid M

(Last) (First) (Middle)

RAPPORT THERAPEUTICS, INC.

99 HIGH STREET, SUITE 2100

(Street)

BOSTON MA 02110

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Rapport Therapeutics, Inc. [ RAPP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/12/2025		P		20,400	A	$24.4791(1)	20,400	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $24.23 to $24.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected.

	/s/ Troy Ignelzi, Attorney-in-Fact	09/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the Rapport Therapeutics (RAPP) Form 4 report?

The Form 4 reports that director Reid M. Huber purchased 20,400 shares of RAPP on 09/12/2025 at a weighted-average price of $24.4791 and now beneficially owns 20,400 shares directly.

At what prices were the RAPP shares purchased?

The shares were purchased at prices ranging from $24.23 to $24.50, with a reported weighted-average price of $24.4791 per share.

Does the Form 4 show any option exercises or derivative transactions for RAPP?

No. Table II for derivative securities shows no transactions; only a non-derivative common stock purchase is reported.

Who signed the Form 4 for Reid M. Huber and when?

The Form 4 was signed by Troy Ignelzi, Attorney-in-Fact, on 09/15/2025 on behalf of the reporting person.

Can I get details of the number of shares bought at each price?

Yes. The filer states the reporting person will provide, upon request, the number of shares purchased at each separate price within the disclosed range.